GET DAILY SIGNALScbdMD (YCBD) Shows +5% Gain as It Diversifies Beyond Hemp
Key Takeaways
- YCBD shares rose roughly 5% over the trailing 30 days, moving from about $0.39 to near $0.42, a modest move relative to the stock's historically elevated volatility.
- The stock remains in a longer-term downtrend, trading near the lower end of a 52-week range of $0.33 to $2.56, with a market capitalization near $4.7 million and a beta of approximately 2.4.
- cbdMD completed its acquisition of Twinlab's operating assets and brands in early November 2026, diversifying the business beyond hemp into legacy vitamins, supplements, and wellness.
- Fiscal 2026 third-quarter net sales grew 20% year over year to $5.6 million, led by 61% wholesale growth and accelerating momentum in the Oasis beverage line.
- Federal hemp regulation remains the central risk, with a stricter THC limit scheduled to take effect November 12, 2026, pending potential legislative changes.
- For deeper data on valuation and fundamentals, explore cbdMD's Price Targets, Earnings, and Forecast on dedicated pages.
- See how top-performing automated strategies are being applied to stocks like YCBD by visiting Tickeron's Trending AI Robots.
Market Snapshot for cbdMD (YCBD)
YCBD closed near $0.42 in early November 2026 after a modest 5% advance over the prior 30 days. That move came after choppy, low-volume trading and stands in contrast to the sharper swings the stock has seen over the past year, when it ranged from above $2.50 down to near $0.33. With a market cap around $4.7 million and a beta near 2.4, this remains a high-volatility micro-cap that can react quickly to news. In my view, the recent uptick reflects early investor interest in the company’s shift toward a wider wellness lineup, though the longer-term downtrend is still intact.
Business Overview and Competitive Position
Headquartered in Charlotte, North Carolina, cbdMD operates in the consumer wellness space with a portfolio that includes hemp-derived CBD products, pet-focused offerings through Paw CBD, functional mushroom supplements via ATRx, and the Oasis line of hemp-derived THC beverages. The Bluebird Botanicals brand, added earlier in 2026, brings additional retail and e-commerce reach. Distribution spans direct-to-consumer, marketplaces, and an expanding wholesale network. Management has emphasized third-party testing and quality standards, and the company has positioned itself as an integrator of acquired brands in a fragmented category. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Developments Driving the Stock
The biggest recent catalyst was the November 2, 2026 completion of the Twinlab asset acquisition, which added established supplement brands including Twinlab, Reserveage, Metabolife, and ResVitale. The deal, executed through a Florida assignment for the benefit of creditors, reduces reliance on hemp-derived products amid regulatory uncertainty. It followed a September agreement and is expected to help push combined revenue toward roughly $30 million annually. Around the same time, Maxim downgraded the shares to Hold from Buy. Operationally, fiscal 2026 third-quarter net sales rose 20% year over year to $5.6 million, driven by 61% wholesale growth and stronger Oasis beverage trends. Gross margin slipped to 54.7% from 61.5% due to channel mix and compliance costs, prompting a cost-reduction initiative targeting $100,000 to $150,000 in monthly savings. The key external factor remains federal hemp rules, with a 0.4 milligram THC-per-container limit set for November 12, 2026, unless legislation intervenes.
2026 Outlook and Key Items to Watch
The central uncertainty is whether the November 12 THC limit takes effect or gets revised through bipartisan legislation. A stricter outcome could weigh on Delta-9 and Oasis revenue, while a favorable change would ease a major overhang for compliant operators. Investors will also want to follow the integration of the Twinlab brands and any combined guidance in upcoming earnings. Margin recovery, cost savings realization, and progress toward the low-to-mid $6 million quarterly cash-breakeven target are additional metrics worth monitoring. Broader factors such as state shipping rules, wholesale mix, and overall wellness demand will continue to influence results. Given the beta near 2.4, general market sentiment and liquidity conditions also matter. From what I see, no single data point should be viewed in isolation.
Using Tickeron AI Tools in My Process
When analyzing volatile micro-caps like this one, I sometimes review Tickeron’s Trending AI Robots to observe how quantitative strategies are positioned across similar names. It offers a quick way to complement fundamental work with data-driven signals without replacing my own research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
YCBD saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for YCBD moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 33 similar instances where the indicator exited the overbought zone. In 33 of the 33 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
YCBD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for YCBD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Indicator exited the oversold zone, 30 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on YCBD as a result. In 86 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for YCBD just turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where YCBD advanced for three days, in 148 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.568) is normal, around the industry mean (7.271). P/E Ratio (1.809) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of beauty shops
Industry PharmaceuticalsGeneric
Advertisement